Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00
Mersana Therapeutics (NASDAQ:MRSN – Free Report) had its price target lifted by Truist Financial from $9.00 to $10.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. MRSN has been the topic of several other reports. Guggenheim reissued a “buy” rating and issued a $5.00 […]
Mersana Therapeutics (NASDAQ:MRSN – Free Report) had its price target lifted by Truist Financial from $9.00 to $10.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. MRSN has been the topic of several other reports. Guggenheim reissued a “buy” rating and issued a $5.00 […]
